| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Poliumoside targets aldose reductase, the enzyme responsible for converting glucose to sorbitol in the polyol pathway. It also inhibits the formation of advanced glycation end products (AGEs), which are implicated in diabetic complications and aging.
|
|---|---|
| ln Vitro |
Poiumoside has an IC50 of 19.69 μM for AGE production and 8.47 μM for RLAR [1]. In vitro, poiumoside (5-30 μM; 3 hours) prevents rat erythrocytes from hemolyzing when exposed to AAPH [2]. In RAW 264.7 cells, poiumoside (12.5-100 μM; 2 hours pretreatment) suppresses the production of TNF-α and IL-6 produced by LPS [3].
In vitro, Poliumoside demonstrates greater inhibitory effects on rat lens aldose reductase than the positive controls 3,3-tetramethyleneglutaric acid and quercetin. It also significantly inhibits AGE formation. |
| ln Vivo |
In zebrafish larvae, poliumoside suppresses vasodilation [1].
In vivo, Poliumoside may have potential for preventing or treating diabetic complications by inhibiting aldose reductase and AGE formation. However, specific in vivo data are limited. |
| Enzyme Assay |
Aldose reductase inhibitory activity is measured using purified rat lens aldose reductase enzyme. The enzyme is incubated with DL-glyceraldehyde as substrate and NADPH as cofactor. Inhibition is determined by measuring the decrease in NADPH oxidation spectrophotometrically at 340 nm.
|
| Cell Assay |
Cell-based assays using cells exposed to high glucose conditions are used to evaluate the inhibition of AGE formation and aldose reductase activity. Cells are treated with Poliumoside, and AGE accumulation or sorbitol levels are measured.
|
| Animal Protocol |
Animal models of diabetes (e.g., streptozotocin-induced diabetic rats) are used to evaluate the effects of Poliumoside on diabetic complications. Parameters such as lens aldose reductase activity, AGE levels, and neuropathy markers are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Poliumoside are not extensively characterized. As a glycoside, it is expected to undergo deglycosylation and metabolism. Oral bioavailability may be limited.
|
| Toxicity/Toxicokinetics |
Specific toxicity data are limited. Phenylethanoid glycosides are generally considered to have a low toxicity profile. No significant adverse effects have been reported at research doses.
|
| References |
|
| Additional Infomation |
It has been reported that [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxacyclohexane-2-yl]oxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxacyclohexane-2-yl]oxymethyl]oxacyclohexane-3-yl](E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid ester is present in Penstemon linarioides, Digitalis purpurea, and other organisms for which data are available.
Poliumoside is a research compound with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of aldose reductase inhibition and AGE inhibition for diabetic complications. |
| Molecular Formula |
C35H46O19
|
|---|---|
| Molecular Weight |
770.7284
|
| Exact Mass |
770.263
|
| CAS # |
94079-81-9
|
| PubChem CID |
10373017
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
1023.2±65.0 °C at 760 mmHg
|
| Flash Point |
316.2±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.685
|
| LogP |
2.63
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
54
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OCCC3=CC(=C(C=C3)O)O)O)O[C@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)C)O)O)O)OC(=O)/C=C/C5=CC(=C(C=C5)O)O)O)O)O
|
| InChi Key |
YMWRMAOPKNYHMZ-LLVTZOIGSA-N
|
| InChi Code |
InChI=1S/C35H46O19/c1-14-24(41)26(43)28(45)33(50-14)49-13-22-31(53-23(40)8-5-16-3-6-18(36)20(38)11-16)32(54-35-29(46)27(44)25(42)15(2)51-35)30(47)34(52-22)48-10-9-17-4-7-19(37)21(39)12-17/h3-8,11-12,14-15,22,24-39,41-47H,9-10,13H2,1-2H3/b8-5+/t14-,15-,22+,24-,25-,26+,27+,28+,29+,30+,31+,32+,33+,34+,35-/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~129.75 mM)
H2O : ~50 mg/mL (~64.87 mM) Ethanol : ~50 mg/mL (~64.87 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2975 mL | 6.4874 mL | 12.9747 mL | |
| 5 mM | 0.2595 mL | 1.2975 mL | 2.5949 mL | |
| 10 mM | 0.1297 mL | 0.6487 mL | 1.2975 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
